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Abstract
Epithelial ovarian cancer (EOC) is a significant cause of cancer related morbidity and mortality in
women. Preferential involvement of peritoneal structures contributes to the overall poor outcome
in EOC patients. Advances in biotechnology, such as cDNA microarray, are a product of the
Human Genome Project and are beginning to provide fresh opportunities to understand the
biology of EOC. In particular, it is now possible to examine in depth, at the molecular level, the
complex relationship between the tumor itself and its surrounding microenvironment.
This review focuses on the anatomy, physiology, and current immunobiologic research of
peritoneal structures, and addresses certain potentially useful animal models. Changes in both the
inflammatory and non-inflammatory cell compartments, as well as alterations to the extracellular
matrix, appear to be signal events that contribute to the remodeling effects of the peritoneal
stroma and surface epithelial cells on tumor growth and spread. These alterations may involve a
number of proteins, including cytokines, chemokines, growth factors, either membrane or non-
membrane bound, and integrins. Interactions between these molecules and molecular structures
within the extracellular matrix, such as collagens and the proteoglycans, may contribute to a
peritoneal mesothelial surface and stromal environment that is conducive to tumor cell
proliferation and invasion. These alterations need to be examined and defined as possible
prosnosticators and as therapeutic or diagnostic targets.
The peritoneum and its structures are integral to the
microenvironment of epithelial ovarian cancer (EOC).
The peritoneum comprises a single layer of mesothelial
cells at the surface, covering abdominal organs (visceral or
serosal layer) and the abdominal and pelvic wall (parietal
layer or peritoneum).
About 80% of the more common epithelial ovarian can-
cers (EOC) involve the peritoneum or serosal surfaces as
microscopic foci and visible lesions. The metastases may
be exophytic with direct exposure to the peritoneal cavity
and its contents or subperitoneal foci coalescing over time
to form variably sized plaque-like deposits (Figure 1).
Involvement of the peritoneum predicates an adverse sit-
uation for the patient that impacts significantly on prog-
nosis as evidenced by the fact that Stage I patients have a
5 and 10 year survival of 90% [1], whereas patients with
Stages III and IV disease have a 5 year survival of about
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Surgical restaging by laparoscopy (peritonoscopy) and histopathologic findings showing different patterns of peritoneal involve- ment following prior systemic chemotherapy Figure 1
Surgical restaging by laparoscopy (peritonoscopy) and histopathologic findings showing different patterns of peritoneal involve-
ment following prior systemic chemotherapy. (A,B) Exophytic peritoneal metastases approximately 1 cm in diameter showing 
multiple capillary loops. Histologic evaluation demonstrates numerous blood vessels surrounded by tumor cells. (C,D) Small 1 
mm sized peritoneal metastases that are subperitoneal on histologic evaluation. (E,F) Multiple metastases about 1 cm in diame-
ter that are growing deep to the peritoneal surface and coalescing to form plaques. Histologic evaluation demonstrates that 
these lesions are relatively avascular and contain significant amounts of peritumoral fibrosis. (Re-printed with permission from 
Cytokines, Cellular & Molecular Therapy).
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20%. Though most patients presenting with advanced dis-
ease show an initial response to chemotherapy, their fates
are ultimately dependent upon sensitivity or resistance to
chemotherapy agents or other factors. The important con-
tributions of the tumor microenvironment to the malig-
nant phenotype has been demonstrated in recent
preclinical tumor models [2-4]. Findings from a recent
study of human EOC tumors also suggest the possibility
of genomic instability in nontumor tissues adjacent to
growing tumor foci in EOC patients [5]. The current
review summarizes the structural and functional compo-
nents of the peritoneum, which could facilitate tumor
progression and metastasis.
Anatomy and physiology of the peritoneum
The peritoneum has the structure and functions of an
organ that is organized for the protection of the integrity
of other abdominal organs and viscera. The surface epi-
thelium of the serous membrane of the peritoneum and
serosa, is attached to a basement membrane lying on a
stroma of variable thickness, and is comprised of colla-
gen-based matrix, blood vessels, lymphatics, nerve fibers,
and, in the normal state, rare hematogenous cells. A
detailed description of the micro and ultra structural anat-
omy is described elsewhere [6,7]. The structural and func-
tional configuration of the peritoneum allows for an
important homeostatic role through rapid mobilization
of inflammatory mechanisms that can efficiently localize
an injury or infection. The peritoneal surface layer has
spaces or stomata between the surface mesothelial cells
that could readily allow transfer of molecules or possibly
cells between the stroma and the peritoneal cavity, or vice
versa.
Immunohistochemically documented structures in the
submesothelial layer include Type I and III collagen,
fibronectin, elastin, and laminin at the basement mem-
brane stromal interface and glycosaminoglycans [6]. Epi-
thelial inclusions, referred to as endosalpingosis, can
occur, though its cause is unknown. Ultrastructurally,
both tight junctions and intercellular spaces are present.
The presence of these junctions can affect the transfer of
particles or cells. Molecules may transit either across or
between the cells to the stromal compartment and vice
versa.
Pathology and altered function of peritoneum in EOC
Peritoneal and serosal seeding is a frequent occurrence in
EOC, but there is little known about the role of the multi-
structured peritoneum in contributing to invasion, metas-
tasis, and tumor proliferation. It is possible, if not proba-
ble, that critical alterations in the peritoneum surface and
stroma precede either lymphatic or hematogenous spread
to distant sites. In EOC patients, there may be substantial
alterations to the peritoneum both at the macroscopic and
submacroscopic levels. Such alterations may include
thickening of the surface membrane with or without
malignant ascites formation and overtly enhanced vascu-
larity. In certain patients, the peritoneum may have a
florid appearance of peritonitis with edema, enhanced
vascularity, and soft adhesions. At the microscopic level,
there may be multilayering of the surface epithelium
(hyperplasia) and an inflammatory infiltrate comprised
of different leukocyte populations. Retroperitoneal fibro-
sis can be extensive and can interfere mechanically with
anatomic structures in extraperitoneal locations, includ-
ing ureters, lymphatics, and the bowel in different
locations.
It would appear that a reorganization of the collagen-
based matrix associated with the malignant process in
EOC patients might accompany an inflammatory cell
reaction. This could be similar to the situation in the per-
itoneum of renal fibrosis, which results in hyperplasia of
the surface layer and extensive macrophage infiltrates into
the stroma [8,9]. Since the peritoneal and serosal mem-
branes lie in proximity to the primary tumor or its metas-
tases, the question could be asked whether soluble
products of tumor masses and nodules might transfer to
the normal surface mesothelial cells and penetrate the
subjacent stromal tissues. Molecules such as cytokines or
chemokines released from the tumor into the peritoneal
cavity could possibly prime these tissues for tumor spread,
proliferation, and metastasis. The peritoneum can easily
permit transperitoneal passage of molecules, even up to
the size of albumin, and, depending on their adherence
and reactivity with stromal compartment structures,
might either transfer to the capillary bed or accumulate in
the subperitoneal compartment, with later entry to the
lymphatics. The dynamics of molecule transfer across the
peritoneum as it applies to intraperitoneal therapy phar-
macology and pharmacodynamics are reviewed elsewhere
[10]. Peritoneal membrane and stromal structures exhib-
iting adherence properties for such molecules or cells,
however, might retard their removal from this site, con-
tributing to a sensitizing effect on the peritoneum.
Dual role of the inflammatory reactions in EOC
There is substantial data to support the presence of
immune cell infiltration in EOC and its microenviron-
ment. In earlier studies, we had shown that T cells com-
prised about 70% of mononuclear leukocytes in solid
EOC tumors [11], and results from a number of experi-
ments by us and by others suggested that the presence of
these T cells could be associated with an antigen-driven
immune response [12-17]. This effect is supported by the
presence of clonally expanded T cell transcripts in ovarian
TIL [18]. Notwithstanding these findings, we [19] and
others [20] have found little evidence for the presence of
an active ongoing adaptive immunity in vivo. This isJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/23
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supported by the absence of IFNγ transcripts in solid
tumors and their infrequent detection in ascitic T cells
[19]. Others have also reported absent CD3 TCRζ on TIL
[20], and absent or low levels of IFNγ protein detected in
ascites of EOC [21]. It is possible that cloned T cells in the
tumor environment could represent tolerized cells,
though antitumor activity can be generated ex vivo when
these T cells are exposed to appropriate activation stimuli
[13,14]. The presence of regulatory T cells [22], and cer-
tain macrophages [23], which are producers of IL6, IL10,
and TGFβ could favor an immunosuppressive environ-
ment and may contribute to tumor progression and
metastases [24]. The role of IL10 remains to be elucidated
as, depending on the status of the tumor, this cytokine can
either enhance or suppress immune responses [25].
Large numbers of monocyte/macrophages (MOMA) are
also present in ascitic fluid where they may comprise 50%
or more of the mononuclear leukocyte population,
whereas the proportion of T-lymphocytes is usually below
40% [11]. In recent preliminary studies, we have found
that pelvic peritoneal biopsies from advanced stage EOC
patients, even in the absence of tumor involvement of the
specimens, also has a high proportion of MO/MA. The
MO/MA in EOC comprise several subsets with the notable
presence of CD14+DR- and CD14+DR+ CD16+ cells [26].
The differentiation potential and functional capacity of
these MO/MA in cancer patients is largely undetermined
but clearly there are differences in the phenotypic charac-
teristics between normal and EOC patients [26]. Inflam-
matory infiltrates have long been observed in human
cancer tissues, but their significance in the non-lymphom-
atous solid tumors has largely been ignored by patholo-
gists and clinicians. There is increasing recognition that
infiltrating immune cells may contribute to either
enhancement of immunity or tumor growth and progres-
sion [24]. Both MO/MA and T cells may have this dual
role, and it remains a challenge to steer the activity of
these populations toward an effective antitumor response
in vivo.
We have recently employed a custom-made standardized
cDNA microarray that utilizes probes for 16,500 genes to
conduct a pilot study on the peritoneum of patients with
EOC [27]. Biopsies were obtained at the time of perito-
neal entry on patients undergoing exploratory surgery for
suspected EOC. For controls, we utilized specimens of
parietal peritoneum obtained at the same sites from
patients undergoing surgery for suspected benign disease.
Results from this study showed that the superficial layer,
including the surface peritoneum and subjacent stroma
specimens from the malignant group, revealed unique
features at the transcript level compared to the benign
group. These features are characterized by a dynamic proc-
ess including cell attachments, signaling, growth stimula-
tion, and, most importantly, a proinflammatory, pro-
angiogenic, and extracellular matrix (ECM) remodeling
effects. The peritoneum and subperitoneal stroma from
the benign cases showed homogeneity in their transcript
expression without the proinflammatory signature con-
trasting with some heterogeneity from patients with EOC,
but an emphasis on inflammatory network responses and
cell infiltrates.
Cytokines and chemokines as facilitators of a protumor 
microenvironment
With increased knowledge in endothelial attachment and
transcapillary migration, there is now a focus on inflam-
matory as well as non-inflammatory cell infiltrates and
their contribution to cancer cell spread. Chemokines and
certain of the larger cytokines may contribute to the
migration of leukocytic and other cells into a tumor envi-
ronment among their other properties. The chemokines
now have a new nomenclature based on their chemical
structure [28], and extensive reviews have been published
[29]. In EOC, particularly in studies on ascites, substantial
amounts of certain CC and CXC chemokines have been
demonstrated, including CCL18 (PARC), CXCL8 (IL8),
CCL2 (MCP1), and CCL3 (MIP1α) [30] (Table 1). Tran-
scripts for CCL4 (MIP1β), CCL5 (RANTES), CCL7
( M C P 3 )  h a v e  b e e n  d e m o n s t r a t e d  i n  E O C  c e l l s  [ 3 1 ]
CCL13, however, is produced by ascitic macrophages and
cannot be induced in EOC cells [30]. Chemokines and
cytokines may have in common potent functional proper-
ties, such as chemotaxis and proangiogenesis, and typi-
cally have effects in proximity to cells producing them.
Larger cytokine molecules, such as TGFβ, may also have
chemotactic and proangiogenic effects. In advanced dis-
ease, tumor cells and other cells of nontumor origin, can
contribute to chemokine production. CXCL8 (IL8) is very
pleiotropic and is constitutively produced or induced by
both hematogenous and non-hematogenous cells and by
hypoxia. We found that CXCL8 was overexpressed on the
peritoneal stroma along with other network genes and
appears to be a pivotal chemokine with substantial inter-
actions at the transcript level with genes that are involved
in inflammation, angiogenesis, and chemotaxis [27,32].
Receptors for the chemokines are expressed on a variety of
hematogenous cells, including T cells and macrophages
[33]. Of interest, CXCR4, the receptor for CXCL12
(SDF1), appears to be selectively expressed on EOC cells
[34] and may contribute to tumor cell migration. There is
a lack of detectable change in expression of other chemok-
ine receptors in response to cytokines, except for CCR2,
the receptor for CCL2 and certain other CC chemokines,
which appears to be downregulated on EOC ascitic mac-
rophages [35]. This effect may interfere with migration of
macrophages away from the tumor site while contributing
to a tumor-promoting environment [35]. Unlike
cytokines, many chemokines may exhibit moreJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/23
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promiscuous binding to receptors. This may insure a
regional effect through their redundancy.
Several cytokines have been detected in serum and ascites
of EOC patients, including TGFβ isotypes, IL10, IL6,
TNFα, CSF1 and IL1 [19,36,37,12,38]. TGFβ isotypes are
produced by EOC cells [39] on mononuclear leukocytes,
including CD14+DR- [23] and T regulatory cells [22].
TGFβ, in its activated form, was previously considered a
tumor-inhibitory cytokine but its tumor-reactive proper-
ties appear to be more complex (Table 2). TGFβ also can
have a tumor promoting effect in advanced cancer possi-
bly through activation of cdk inhibitors that block the
unbinding of the pRb/E2F transcripts [40], and interfer-
ence with TGFβ receptor binding mediated by H-Ras, as
well as consequent to c-myc, its reaction with the E2F tran-
scription factor complex [40]. The signaling pathway of
TGFβ within tumor cells may also be subverted due to
mutations, or interactions with other cytokines. A TGFβ
activation response might, however, prevail in the micro-
environment where it may contribute to myofibroblast
and endothelial cell chemotaxis, tumor adhesion, and
suppression of adaptive and innate immunity [41]. IL10 is
also produced in association with EOC with a large con-
tribution by CD14+DR- MO/MA, and these cells may
function as immune regulatory cells. IL6 is expressed by
EOC tumor cells as well as mesothelial cells and has been
detected in the serum and ascites of EOC cells [42-45]. A
recent study has shown that IL6 and MCP production by
submesothelial cells can be enhanced during abdominal
surgery [46]. IL6 also enhances tumor attachment and
proliferation of tumor cells, most likely through the PI 3-
K activation mechanisms, and can interfere with the mat-
uration of MO/MA to DC [44,45]. This finding might con-
tribute to the large number of functionally immature DC
in the ascitic fluid and absent levels of IL12, a product of
DC maturation [47,48] (and C Butts' unpublished
observations).
Factors associated with compostition and decomposition 
of the extracellular matrix (ECM)
Phenotypic and functional characterization of stromal
inflammatory and non-inflammatory cell infiltrates will
be useful for understanding the biology of metastasis.
These infiltrates probably occur following transcapillary
migration. In this respect, the chemical composition and
dynamics of the extracellular matrix (ECM) are also likely
to be important. Thus, chemokines may "stick" to other
proteins in the stromal microenvironment, enhancing
their chemoattraction and other properties by accumulat-
ing at these sites. Proteoglycans, which comprise a protein
core, and sulphated or non-sulphated aminoglycan side
chains could facilitate this. The proteoglycans include a
variety of molecules, such as versican, decorin, hyaluran,
and heparan with different side chains. The side chain of
decorin can be of the dermatin type or chondroitin SO4
type, each having non-overlapping different functions.
We have previously shown that decorin chondroitin SO4
is expressed with myofibroblasts in the adjacent stroma of
EOC tissues [49] (Figure 2). A recent paper has shown that
endothelial cells stimulated in culture on a collagen type
I matrix in the presence of IL6 and IL10 synthesized deco-
rin [50]. This is of particular interest since both IL6 and
IL10 are highly expressed in EOC. Chemokines may
attach covalently to proteoglycans that express GAG
sequences, while retaining their effects on tumor microen-
vironment cells. This may facilitate their effects locally. In
contrast, proteoglycans might also interfere with the bind-
ing of activated TGFβ to its receptors.
A large family of receptors called integrins can regulate
many functions at both the cellular and ECM levels. The
integrins are important for the spread and proliferation of
cancer cells [2]. Their functions, however, are complex
since integrins can associate with other integrins or
growth factor receptors or adaptive proteins producing bi-
directional effects to and from the cell membrane surface.
Integrin mediated effects include cytoskeletal changes
through complexing with α actinin and other proteins
with downstream effects on actin. These changes may
Table 1: Chemokines/Receptors in EOC
Ligand (Alt. Name) Receptors Cells Targeted Correlates in EOC
CCL2 (MCP1) *+ CCR2 Activated T, Monocytes, DC, Basophils CD8+ T cells, CD68+ MA ↓ on ascitic MA
CCL3 (MIP1α)*+ CCR2 Activated T, NK, MO, Eosinophils
CCL4 (MIP1β)*+ Unknown
CCL5 (RANTES) * CCR2 Activated T, NK, MO, Eosinophils
CCL7 (MCP3) + CCR2
CCL18 (PARC) + Unknown MA produced but not induced in EOC cells
CXCL8 (IL8) *+ CXCR1, CXCR2 Neutrophils, Resting T
CXCL12 (SDF1) *+ CXCR4 Neutrophils, Resting T, Activated T, B, MO CXCR4 preferentially expressed on EOC cells
* In RNA detected on EOC cell lines + Proteins detected in ascitesJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/23
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affect cell survival, proliferation, motility, and differentia-
tion. Depending upon the particular signaling pathway
dominance, the downstream effect may be either repres-
sion or activation of a particular function. Integrins may
modulate or enhance the expression of other integrins
and receptors, e.g. β1 and β3 integrins, which can influ-
ence apoptosis. Lack of detection of the cell-to-cell
adhesion molecule E-cadherin on cuboidal cells of ovar-
ian surface epithelium in contrast to its upregulated
expression on metaplastic intra-ovarian cystic glands and
early well-differentiated glandular carcinoma suggest that
the latter cells may have been derived from the migrating
surface ovarian cells [51]. E-cadherin also inhibits the
anti-apoptotic PI3K signaling pathway and E-cadherin
expression in advanced EOC metastatic nodules appears
to be less prominent than other cadherin molecules [52].
In a 3-D model of breast cancer, chronic activation of the
β1 integrin has been shown to enhance the cancer pheno-
type in contrast to a different signaling effect from α6/β4
integrin activation, leading to suppression of the cancer
phenotype. In advanced EOC, the reduction or loss of E-
cadherin expression is hypothesized to contribute to the
spread and progression of the tumor [52]. E-cadherin in
both breast and ovarian cancers is considered a late tumor
suppressor molecule. The importance of β1 signaling has
been shown in experiments that demonstrate reversion of
the malignant phenotype when β1 integrin is blocked
with anti β1 mAbs [53]. These findings overall suggest
that altered expression of adhesion molecules, such as
cadherein, could serve different functions during the
pathogenesis of the EOC disease process. Antibody-medi-
ated inhibition of integrin 1 has also been shown to
interefere with production of decorin which is an impor-
tant part of the ECM [50].
Animal models for EOC/peritoneal interactions
Representative animal models of EOC need to combine
the oncogenic developmental pathways as well as contri-
butions from the cellular and ECM environment of the
epithelium and stroma. This relationship, however, is
clearer in established virally induced tumors [4].
There has been some recent progress in the development
of suitable mouse models for human ovarian cancer
[54,55]. Because of marked heterogeneity of ovarian can-
cer both at histopathologic and clinical levels, the under-
lying mechanisms that produce the altered gene
expression profile in the EOC is not clear. However, it is
reasonable to assume that the altered gene expression pro-
file is at least in part due to activation of oncogenic events
that transform the ovarian surface epithelial cells. Toward
this end, it has been shown that oncogenic HRASV12 or
KRASV12 activates multiple proinflammtory cytokines and
angiogenic factor cytokines during the malignant transfor-
mation of ovarian surface epithelial cells in a newly
created genetically defined model for ovarian cancer. In
this model, introduction of SV40 T/t antigen extended the
life span of primary cultured ovarian surface epithelial
cells for a few more passages; however, these T/t antigen-
expressing cells are still mortal. Introduction of the cata-
Table 2: Dual Effects of Cytokines on Tumor/Tumor Microenvironment
TGFβ IL6
• TGFβ + TGFβ RIII → TGFβ - RII + RI heterodimer → TGFβ RI - P + SMADs → SMAD - P → nucleus → 
initiates transcription
• TGFβ → in repression cell cycle genes or activation
• Repression involves activation of cycle dependent kinase inhibitors, blocks unbinding of pRb/E2F 
transcripts
• Other interactions include:
H-Ras (↓ RI & ↑ RII);
C-Myc (stimulates proliferation by repressing cdk inhibitors) associates w/E2F transcript factor complex
• TGFβ effect negated by disruption of signal pathway
• Alterations to the microenviroment
Tumor adhesion
Endothelial chemotaxis (proangiogenic)
Myofibroblast chemotaxis
• Immunosuppressive Effects
Adaptive
↓ MHC expression (targeting)
↓ Costimulatory Ag expression by DC
Blocks pre CTL → CTL
Suppresses TH1 cells - Shift to TH2
Induces apoptosis
Suppresses proliferative response to APCs
Innate Cells
Inhibits NK & MA activation
• ↑ TuC attachment migration
• Immune modulation (T-cell ↑)
• Interferes w/MA maturation to DC
• Proliferation thru P13-K activation
IL10
• ↓ MHC expression on TC
• ↓ Costimulatory Ag expression
• Suppress cytotoxic T-cell activation
• Inhibits IFNγ production
• Inhibits T-cell productionJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/23
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lytic subunit of telomerase (hTERT) results in immortali-
zation of these cells. Introduction of HRASV12 or KRASV12
results in transformation of these cells as reflected on the
increased number of anchorage independent growth and
tumor development after subcutaneous injection of these
cells. Peritoneal injection of the transformed cells pro-
duced undifferentiated carcinoma or malignant mixed
mullerian tumor and developed ascites, the tumor cells
are focally positive for CA125 and mesothelin. Gene
expression profile analysis of transformed cells revealed
elevated expression of several cytokines including inter-
leukin (IL)-1β, IL6, and IL8, that are up-regulated by the
NF-κB pathway, which is known to contribute to naturally
occurring human EOC. Incubation with antibodies to IL-
1β or IL8 led to apoptosis in the ras-transformed cells and
ovarian cancer cells but not in immortalized cells that had
not been transformed. Thus, the transformed human
ovarian surface epithelial cells recapitulated many fea-
tures of natural ovarian cancer including a subtype of
ovarian cancer histology, formation of ascites, CA125
expression, and NF-κB-mediated cytokine activation.
These cells provide a novel model system to study human
ovarian cancer. Because of the remarkable similarity of
gene expression between the RAS-transformed ovarian
surface epithelial cells and peritoneum associated with
ovarian cancer, these immortalized preneoplastic ovarian
epithelial cell lines may provide a valuable experimental
tool to examine the role of each of the cytokines in the
peritoneum during ovarian cancer development [54].
Histochemical staining of human ovarian tissue with anti-6-sulfate chondroitin or anti-smooth muscle α-actin antibody Figure 2
Histochemical staining of human ovarian tissue with anti-6-sulfate chondroitin or anti-smooth muscle α-actin antibody. Serial 5-
µm sections of paraffin-embedded tumors were stainead with anti-6-sulfate chondroitin (A) or anti-smooth muscle α-actin (B). 
Arrows point to regions of staining overlap. (Re-printed with permission from Clinical Cancer Research).
A.  Ovarian cancer--anti-6-sulfate
chondroitin
B.  Ovarian cancer--anti-smooth 
muscle α α α α-actinJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/23
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Susceptibility of the stromal compartment of the perito-
neum to proliferative signals has been well documented
in animal models of the peritoneal fibrosing syndrome
following exposure to chemical peritoneal dialysates
[9,56]. In these models, alterations to the stromal envi-
ronment occur in response to the dialysate resulting in
infiltration of two main cell populations, fibroblasts
secreting MCP-1, VEGF, and HSP47 and macrophages
which can express TGFβ, TNFα, IL1 and fibronectin. Mac-
rophages in these models were shown to be recruited by
several CC chemokines, MCP-1, RANTES, and MIP-1 and
collagen-dependent endothelial cells. Moreover, removal
of the fibroblast element in a knockout animal model
abrogated the MA infiltration and the fibrotic process. A
similar process has been described in renal fibrosis, which
also involves mononuclear leukocytes and myofibrob-
lasts. In EOC, it is possible that molecules derived from
the primary or peritoneal surface metastases could be dis-
tributed throughout the peritoneal cavity. Even in the
absence of ascites, the distribution of these molecules
could possibly be facilitated by negative pressure in the
peritoneal cavity and peristalsis of the intestines. The pre-
cise mechanisms underlying the formation of ascites is
unknown. Ascites indicate a more advanced stage of the
disease which could be a consequence of alterations in
permeability of the peritoneum or extensive lymphatic
obstruction. In subperitoneal metastatic growth, the
ascites may be almost acellular whereas surface exophytic
lesions may be accompanied by large numbers of free-
floating tumor cells, mesothelial cells and leukocytes, and
in some cases, the ascites has a hemorrhagic appearance.
In summary, we have shown that peritoneal structures of
patients with EOC are different at the transcript level from
those of patients with benign conditions [27]. The
changes observed reflect alterations in cytoskeletal and
signaling pathways that suggest regional activity from
integrins, cytokines, hormone growth factors, and adap-
tive proteins. In addition, there appears to be intense
chemokine activity, particularly of the CXC motif chem-
okines, suggesting a pattern of chemotactic influence on
leukocytic as well as other cell types. Enhanced
collagenase activity would contribute to remodeling of
the stromal compartment and creation of a favorable
environment for infiltration of leukocytes as well as other
cells, such as myofibroblasts and endothelial cells. Gene
profiling of the peritoneum may provide hints about early
transition steps to cancer or provide insight into changes
that may actually facilitate the spread of cancer to adjoin-
ing tissues. It is anticipated that future studies using high
throughput technologies with a multidimensional
approach will enhance understanding of these alterations
and their biological significance. These efforts could help
identify critical alterations in the environment surround-
ing the cancer and its metastases and might ultimately
lead to advances in diagnosis, prognosis, and novel
approaches to therapeutic targeting in EOC.
The past few decades have seen considerable progress in
chemotherapeutics of EOC that are contributing to an
overall reduction in mortality [57]. However, EOC is het-
erogenous in its histopathology and sensitivity to chemo-
therapy. In order to overcome redundancies in the
pathways and networks that control tumor cell growth, it
will be necessary to employ multitargeted therapeutic
strategies. A number of peritoneal structures could serve as
useful potential targets, including inflammatory and non-
inflammatory stromal cells, as well as production of mol-
ecules in the ECM, such as chemokines [29]. In vitro
experiments suggest that the microenvironment can
influence the malignant phenotype. It is also likely that
malignant cells from the primary tumor or metastasis
might modify the microenvironment, preparing both sur-
face epithelial and stromal cells to support the growth and
proliferative activity of the tumor. Thus, future strategies
should attempt to identify those pathways and networks
in the microenvironment that are critical to tumor cell
survival.
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